Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

MmpL3 as a Target for the Treatment of Drug-Resistant Nontuberculous Mycobacterial Infections.

Li W, Yazidi A, Pandya AN, Hegde P, Tong W, Calado Nogueira de Moura V, North EJ, Sygusch J, Jackson M.

Front Microbiol. 2018 Jul 10;9:1547. doi: 10.3389/fmicb.2018.01547. eCollection 2018.

2.

A Simple and Efficient Approach for the Synthesis of 2-Aminated Quinazoline Derivatives via Metal Free Oxidative Annulation.

Pandya AN, Villa EM, North EJ.

Tetrahedron Lett. 2017 Mar 29;58(13):1276-1279. doi: 10.1016/j.tetlet.2017.02.033. Epub 2017 Feb 12.

3.

Design, synthesis and evaluation of indole-2-carboxamides with pan anti-mycobacterial activity.

Franz ND, Belardinelli JM, Kaminski MA, Dunn LC, Calado Nogueira de Moura V, Blaha MA, Truong DD, Li W, Jackson M, North EJ.

Bioorg Med Chem. 2017 Jul 15;25(14):3746-3755. doi: 10.1016/j.bmc.2017.05.015. Epub 2017 May 8.

4.

Synergistic Interactions of MmpL3 Inhibitors with Antitubercular Compounds In Vitro.

Li W, Sanchez-Hidalgo A, Jones V, de Moura VC, North EJ, Jackson M.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02399-16. doi: 10.1128/AAC.02399-16. Print 2017 Apr.

5.

Therapeutic Potential of the Mycobacterium tuberculosis Mycolic Acid Transporter, MmpL3.

Li W, Obregón-Henao A, Wallach JB, North EJ, Lee RE, Gonzalez-Juarrero M, Schnappinger D, Jackson M.

Antimicrob Agents Chemother. 2016 Aug 22;60(9):5198-207. doi: 10.1128/AAC.00826-16. Print 2016 Sep.

6.

Opportunities and Challenges for Natural Products as Novel Antituberculosis Agents.

Farah SI, Abdelrahman AA, North EJ, Chauhan H.

Assay Drug Dev Technol. 2016 Jan-Feb;14(1):29-38. doi: 10.1089/adt.2015.673. Epub 2015 Nov 13. Review.

PMID:
26565779
7.

Covalent modification of the Mycobacterium tuberculosis FAS-II dehydratase by Isoxyl and Thiacetazone.

Grzegorzewicz AE, Eynard N, Quémard A, North EJ, Margolis A, Lindenberger JJ, Jones V, Korduláková J, Brennan PJ, Lee RE, Ronning DR, McNeil MR, Jackson M.

ACS Infect Dis. 2015 Feb 13;1(2):91-97.

8.

Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis.

Li W, Upadhyay A, Fontes FL, North EJ, Wang Y, Crans DC, Grzegorzewicz AE, Jones V, Franzblau SG, Lee RE, Crick DC, Jackson M.

Antimicrob Agents Chemother. 2014 Nov;58(11):6413-23. doi: 10.1128/AAC.03229-14. Epub 2014 Aug 18.

9.

In vitro and in vivo activities of HPi1, a selective antimicrobial against Helicobacter pylori.

Gavrish E, Shrestha B, Chen C, Lister I, North EJ, Yang L, Lee RE, Han A, Williams B, Charnuska D, Coleman K, Lewis K, LaFleur MD.

Antimicrob Agents Chemother. 2014 Jun;58(6):3255-60. doi: 10.1128/AAC.02573-13. Epub 2014 Mar 31.

10.

A screen for and validation of prodrug antimicrobials.

Fleck LE, North EJ, Lee RE, Mulcahy LR, Casadei G, Lewis K.

Antimicrob Agents Chemother. 2014;58(3):1410-9. doi: 10.1128/AAC.02136-13. Epub 2013 Dec 16.

11.
12.

Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3-heteroaryl ureas with improved in vitro pharmacokinetic properties.

North EJ, Scherman MS, Bruhn DF, Scarborough JS, Maddox MM, Jones V, Grzegorzewicz A, Yang L, Hess T, Morisseau C, Jackson M, McNeil MR, Lee RE.

Bioorg Med Chem. 2013 May 1;21(9):2587-99. doi: 10.1016/j.bmc.2013.02.028. Epub 2013 Feb 26.

13.

Plastics and environmental health: the road ahead.

North EJ, Halden RU.

Rev Environ Health. 2013;28(1):1-8. doi: 10.1515/reveh-2012-0030. Review.

14.

Screening a library of 1600 adamantyl ureas for anti-Mycobacterium tuberculosis activity in vitro and for better physical chemical properties for bioavailability.

Scherman MS, North EJ, Jones V, Hess TN, Grzegorzewicz AE, Kasagami T, Kim IH, Merzlikin O, Lenaerts AJ, Lee RE, Jackson M, Morisseau C, McNeil MR.

Bioorg Med Chem. 2012 May 15;20(10):3255-62. doi: 10.1016/j.bmc.2012.03.058. Epub 2012 Mar 31.

15.

Base-catalyzed direct conversion of dipyrromethanes to 1,9-dicarbinols: a [2 + 2] approach for porphyrins.

Terazono Y, North EJ, Moore AL, Moore TA, Gust D.

Org Lett. 2012 Apr 6;14(7):1776-9. doi: 10.1021/ol300267j. Epub 2012 Mar 15.

PMID:
22420376
16.

Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane.

Grzegorzewicz AE, Pham H, Gundi VA, Scherman MS, North EJ, Hess T, Jones V, Gruppo V, Born SE, Korduláková J, Chavadi SS, Morisseau C, Lenaerts AJ, Lee RE, McNeil MR, Jackson M.

Nat Chem Biol. 2012 Feb 19;8(4):334-41. doi: 10.1038/nchembio.794.

17.

The structure-activity relationship of urea derivatives as anti-tuberculosis agents.

Brown JR, North EJ, Hurdle JG, Morisseau C, Scarborough JS, Sun D, Korduláková J, Scherman MS, Jones V, Grzegorzewicz A, Crew RM, Jackson M, McNeil MR, Lee RE.

Bioorg Med Chem. 2011 Sep 15;19(18):5585-95. doi: 10.1016/j.bmc.2011.07.034. Epub 2011 Jul 24.

18.

Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors.

North EJ, Howard AL, Wanjala IW, Pham TC, Baker DL, Parrill AL.

J Med Chem. 2010 Apr 22;53(8):3095-105. doi: 10.1021/jm901718z.

PMID:
20349977
19.

Autotaxin structure-activity relationships revealed through lysophosphatidylcholine analogs.

North EJ, Osborne DA, Bridson PK, Baker DL, Parrill AL.

Bioorg Med Chem. 2009 May 1;17(9):3433-42. doi: 10.1016/j.bmc.2009.03.030. Epub 2009 Mar 21.

20.

Molecular recognition in the sphingosine 1-phosphate receptor family.

Pham TC, Fells JI Sr, Osborne DA, North EJ, Naor MM, Parrill AL.

J Mol Graph Model. 2008 Jun;26(8):1189-201. doi: 10.1016/j.jmgm.2007.11.001. Epub 2007 Nov 17.

21.

An appointments system in general practice.

North EJ.

Aust Fam Physician. 1980 Mar;9(3):197-9.

PMID:
7369952
22.

Teaching the psychological aspects of dentistry for children.

NORTH EJ.

J Dent Educ. 1949 Jan;13(2):111-6. No abstract available.

PMID:
18113604

Supplemental Content

Loading ...
Support Center